A Phase II Open-Label, Single-arm, Two-Stage, Multicenter Trial of Pracinostat in Combination With Azacitidine in Elderly (Age 65 Years or Older) Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

Trial Profile

A Phase II Open-Label, Single-arm, Two-Stage, Multicenter Trial of Pracinostat in Combination With Azacitidine in Elderly (Age 65 Years or Older) Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Jun 2017

At a glance

  • Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Pracinostat (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Sponsors Helsinn Healthcare SA; MEI Pharma
  • Most Recent Events

    • 25 Jun 2017 Results (n=41) assessing the impact of somatic mutations and their clearance on disease response and survival outcomes, presented at the 22nd Congress of the European Haematology Association
    • 06 Jun 2017 Results of genetic mutation analysis (n=41) in elderly patients with acute myeloid leukemia treated with azacitidine and pracinostat, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 05 Jun 2017 According to a MEI Pharma media release results from a genetic mutation analysis are being presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top